Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Mar 20, 2025
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-03-18$0.60/sh−8,551$5,122→ 201,026 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 155,821 RSUs.